In short
Ttx-030 has been studied in clinical trials for people with metastatic pancreatic adenocarcinoma who had not received prior treatment. These trials look at whether adding Ttx-030, with or without budigalimab, to chemotherapy can improve outcomes such as progression-free survival and assess safety.
Key points
- Ttx-030 has been studied in a Phase 2 trial for metastatic pancreatic adenocarcinoma. The trial included patients who had not been treated before and compared chemotherapy alone with chemotherapy plus Ttx-030, with or without budigalimab. The study was open-label, multicenter, and randomized, meaning treatment groups were assigned by chance and the trial was done at more than one site. The main outcome was progression-free survival, which measures how long the cancer stays from getting worse. The trial was completed and enrolled 173 people.
Trial overview
The main clinical trial for Ttx-030 in the source data was an open-label, multicenter, randomized Phase 2 study in people with metastatic pancreatic adenocarcinoma who had not been treated before.
This trial was designed to assess the efficacy and safety of Ttx-030 added to chemotherapy, with or without budigalimab, compared with chemotherapy alone.
Who was studied
The trial focused on patients with metastatic pancreatic adenocarcinoma, which means pancreatic cancer that had spread to other parts of the body.
It studied people who were not previously treated for this cancer, so the results apply to patients starting treatment for the first time in this setting.
Treatments compared
The study had three treatment groups: chemotherapy alone, chemotherapy plus Ttx-030, and chemotherapy plus Ttx-030 with budigalimab.
The chemotherapy backbone in the trial was nab-paclitaxel plus gemcitabine, which were given by intravenous infusion.
Budigalimab was included in one of the study arms, so the trial also looked at whether adding this extra treatment changed the results compared with the other groups.
What was measured
The main outcome was progression-free survival (PFS), which is the length of time a patient lives without the cancer getting worse.
This endpoint helps researchers see whether the study treatment may delay cancer growth or spread compared with the control group.
The trial also aimed to assess safety, which means it looked at how well patients tolerated the treatment in the study setting.
Trial status and size
The trial was completed and enrolled 173 participants.
Because it was a multicenter study, the trial was carried out at more than one site, which can help include a broader group of patients and make the results more useful in practice.
What this means for patients
Based on the source data, Ttx-030 has been tested as part of a treatment plan for people with advanced pancreatic cancer who had not received prior therapy.
The study was built to compare different treatment combinations, so it can help researchers understand whether adding Ttx-030, with or without budigalimab, may improve the time before the cancer gets worse.